AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Announce Acceptance of Submission of Feraheme(R) Marketing Authorization Application to the European Medicines Evaluation Agency

LEXINGTON, Mass. & OSAKA, Japan--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Takeda Pharmaceutical Company Limited (TSE: 4502) today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.